Cardiology
Evaluating Bleeding Risks of Asundexian in Noncardioembolic Ischemic Stroke or High-Risk TIA: Insights from the OCEANIC-STROKE Trial
The OCEANIC-STROKE randomized trial demonstrates that adding asundexian to antiplatelet therapy reduces ischemic stroke without a significant rise in major bleeding, though it increases lower gastrointestinal bleeding in patients with nonca
